케토코나졸 관련 안드로겐성 탈모증
A 근거 여러 대규모 임상 시험이 일관되게 유의미한 효과를 보여줍니다.총 5,154명의 참여자를 대상으로 한 17건의 연구(메타분석 3건, RCT 2건)에 근거합니다. 17건 중 16건의 연구에서 긍정적인 효과가 나타났습니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Dketoconazole\u0026condition\u003Dandrogenetic\u002Dalopecia';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
결론
Ketoconazole shampoo has strong evidence supporting its use for androgenetic alopecia, working through both antifungal and anti-androgenic mechanisms, and is recommended as a complement to other hair loss approaches.
- 16 out of 17 studies show positive effects across 5,154 participants
- Works through dual mechanisms: antifungal scalp benefits and local anti-androgenic activity
- Included in clinical guidelines as a complementary approach for pattern hair loss
- Typically used as a 1-2% shampoo applied 2-3 times per week
Key Study Findings
Review
Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights.
Dose: None
vs: None
Outcome: scalp microbiome alterations in androgenetic alopecia
효과: None
None
대상 집단: patients with androgenetic alopecia
laboratory/in vitro
26 weeks
Personalized Compounded Hair Loss Treatments: A Compatibility Assessment of the TrichoConcept™ Vehicle Line.
Dose: F1: biotin 0.5%, caffeine 2.0%, niacinamide 2.0%; F2: finasteride 0.1%, minoxidil 1.0%, tretinoin 0.
vs: Placebo
효과: F1 and F3 stable for 180 days; F2 stable for 14 days; F4 and F5 stable for 150 days; F6/F7 stable fo
None
Review
A Canadian Consensus on Androgenetic Alopecia: Approach and Management.
Dose: None
vs: Placebo
효과: None
None
systematic review
Management of androgenic alopecia: a systematic review of the literature.
Dose: various across 141 included studies
vs: Placebo
효과: multiple treatments shown to successfully promote hair growth; superiority of multifaceted individua
None
Systematic Review
n=318
Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review.
Dose: None
vs: Placebo
효과: Increased hair shaft diameter; significant increase in pilary index; clinical improvement by photogr
None
narrative review
Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris.
Dose: varies
vs: Placebo
효과: None
None
Key Statistics
19
연구
5154
참여자
↑
Positive
A
등급
Referenced Papers
Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights.
Review
International journal of …
2026
Journal of cutaneous …
2025
2 인용
International journal of …
2025
Journal of cosmetic …
2024
11 인용
Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review.
Systematic Review
Dermatologic therapy
2020
34 인용
American journal of …
2020
24 인용
Alternative therapies in …
2020
11 인용
Topical ketoconazole: a systematic review of current dermatological applications and future developments.
Systematic Review
The Journal of …
2019
73 인용
Pharmaceutics
2019
7 인용
The Journal of …
2018
69 인용
Female pattern hair loss.
Review
Current problems in …
2015
8 인용
ISRN pharmacology
2014
22 인용
Androgenetic alopecia.
Review
Giornale italiano di …
2014
8 인용
International journal of …
2013
Skin therapy letter
2012
100 인용
ISRN dermatology
2011
Clinics in dermatology
2010
Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity.
Other
Journal of dermatological …
2007
39 인용
Georgian medical news
2007
The Journal of …
2005
24 인용
Medical hypotheses
2004
21 인용
The Journal of …
2002
96 인용
International journal of …
2002
53 인용
Dermatology (Basel, Switzerland)
1998
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- topical:
- 2% shampoo, 2-3x/week
상한량: Topical only for hair loss
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Negative | -- |
| F1: biotin 0.5%, caffeine 2.0%, niacinamide 2.0%; F2: finasteride 0.1%, minoxidil 1.0%, tretinoin 0. | 26 weeks | Positive | -- |
| None | -- | Positive | -- |
| various across 141 included studies | -- | Positive | -- |
| None | -- | Positive | 318 |
| varies | -- | Positive | -- |
| dutasteride and ketoconazole at pharmacokinetic study doses in rats (not specified in abstract) | -- | Mixed | -- |
| various topical ketoconazole formulations | -- | Positive | 4566 |
권장 복용 시간: Lather on scalp and leave for 3-5 minutes before rinsing; use 2-3 times per week
Safety & Side Effects
보고된 부작용
- ⚠ Scalp dryness and irritation
- ⚠ Changes in hair texture
- ⚠ Oily or dry scalp (paradoxical)
- ⚠ Contact dermatitis (rare)
알려진 상호작용
- ● Other topical hair treatments (apply at separate times)
- ● Systemic ketoconazole has many interactions but topical has minimal systemic absorption
일일 최대 섭취 허용량: Topical only for hair loss
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 케토코나졸 help with 안드로겐성 탈모증?
Based on 19 studies with 5,154 participants, there is strong evidence from multiple clinical trials that 케토코나졸 may support 안드로겐성 탈모증 management. Our evidence grade is A (Strong Evidence).
How much 케토코나졸 should I take for 안드로겐성 탈모증?
Studies have used various dosages. A commonly studied range is 2% shampoo, 2-3x/week. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 케토코나졸?
Reported side effects may include Scalp dryness and irritation, Changes in hair texture, Oily or dry scalp (paradoxical), Contact dermatitis (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 케토코나졸 and 안드로겐성 탈모증?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 19 peer-reviewed studies with 5,154 total participants. The overall direction of effect is positive.
Related Evidence
케토코나졸 다른 건강 상태에 대한 근거
References
- [1] Aditya K Gupta et al.. Int J Dermatol. 2026. Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights. doi:10.1111/ijd.70365 PubMed
- [2] Ian Landells et al.. J Cutan Med Surg. 2025. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. doi:10.1177/12034754251368849 PubMed
- [3] Carolina Schettino Kegele et al.. Int J Pharm Compd. 2025. Personalized Compounded Hair Loss Treatments: A Compatibility Assessment of the TrichoConcept™ Vehicle Line. PubMed
- [4] Amanda Rosenthal et al.. J Cosmet Laser Ther. 2024. Management of androgenic alopecia: a systematic review of the literature. doi:10.1080/14764172.2024.2362126 PubMed
- [5] Jaime R Fields et al.. Dermatol Ther. 2020. Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. doi:10.1111/dth.13202 PubMed
- [6] Dustin H Marks et al.. Am J Clin Dermatol. 2020. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. doi:10.1007/s40257-019-00493-z PubMed
- [7] Solmaz Asnaashari et al.. Altern Ther Health Med. 2020. Herbal Medicines For Treatment of Androgenic Alopecia. PubMed
- [8] Franchesca D Choi et al.. J Dermatolog Treat. 2019. Topical ketoconazole: a systematic review of current dermatological applications and future developments. doi:10.1080/09546634.2019.1573309 PubMed
- [9] Seong-Wook Seo et al.. Pharmaceutics. 2019. In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole. doi:10.3390/pharmaceutics11120673 PubMed
- [10] Motomu Manabe et al.. J Dermatol. 2018. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. doi:10.1111/1346-8138.14470 PubMed
- [11] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
- [12] Muhsin A Aldhalimi et al.. ISRN Pharmacol. 2014. Promotive effect of topical ketoconazole, minoxidil, and minoxidil with tretinoin on hair growth in male mice. doi:10.1155/2014/575423 PubMed
- [13] B M Piraccini et al.. G Ital Dermatol Venereol. 2014. Androgenetic alopecia. PubMed
- [14] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
- [15] K J McElwee et al.. Skin Therapy Lett. 2012. Promising therapies for treating and/or preventing androgenic alopecia. PubMed
- [16] A W Rafi et al.. ISRN Dermatol. 2011. Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. doi:10.5402/2011/241953 PubMed
- [17] Andreas D Katsambas et al.. Clin Dermatol. 2010. Hormonal therapy for acne: why not as first line therapy? facts and controversies. doi:10.1016/j.clindermatol.2009.03.006 PubMed
- [18] Shigeki Inui et al.. J Dermatol Sci. 2007. Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity. doi:10.1016/j.jdermsci.2006.08.011 PubMed
- [19] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
- [20] Ju Jiang et al.. J Dermatol. 2005. Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. doi:10.1111/j.1346-8138.2005.tb00756.x PubMed
- [21] B S Hugo Perez. Med Hypotheses. 2004. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. doi:10.1016/s0306-9877(03)00264-0 PubMed
- [22] Sujay Khandpur et al.. J Dermatol. 2002. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. doi:10.1111/j.1346-8138.2002.tb00314.x PubMed
- [23] C Piérard-Franchimont et al.. Int J Cosmet Sci. 2002. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. doi:10.1046/j.1467-2494.2002.00145.x PubMed
- [24] C Piérard-Franchimont et al.. Dermatology. 1998. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. doi:10.1159/000017954 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.